# immunotherapy

Merck’s PD‑1 Drug Pembrolizumab Wins China Approval as First‑Line Option for dMMR Advanced Endometrial Cancer

Merck’s pembrolizumab (KeRuida®) has been approved by China’s NMPA for first‑line use with carboplatin and paclitaxel, followed by pembrolizumab maintenance, in adults with dMMR advanced or recurrent endometrial cancer. The approval, based on phase III KEYNOTE‑868 (NRG‑GY018) data, shifts immunotherapy into the front line for this biomarker‑defined subgroup and raises issues of testing, reimbursement and market competition.